Published October 28, 2022 | Version v1

FAIR Obstacles for Curating SARS-CoV-2M-Protease Inhibitors

Authors/Creators

  • 1. Medicines Discovery Catapult

Description

Presented at  BioIT World Europe,  Berlin,  October 2022

Despite COVID-19 vaccine successes there is an urgent need for small-molecule antivirals such as the recent Pfizer M-protease (M-prot) inhibitor nirmatrelvir, PF-07321332 exemplified  in PMID34726479 and WO2021250648. Since 2020 the Guide to Pharmacology and BindingDB have collaborated on curating FAIR database entries for clinical candidate M-Prot inhibitors from papers and patents. Patterns of FAIR disclosure are patchy varying from open science data from the COVID Moon-shot consortium, a paper (but no patent) for Shionogi  S-217622 but blinding (neither paper nor patent) of SH-879 from Sosei Heptares.  Challenges of extracting and mapping chemical structures between papers and patents for M-Prot lead inhibitors will be outlined

Files

Files (3.1 MB)

Name Size
md5:13cebe5bbd90bda956432b138f2a4d47
3.1 MB Download